Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial

OBJECTIVE: Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1–3. This analysis compared efficacy and safety of axitinib plus gemcitabine in patients with advanced pancreatic cancer from Japan, North America and the European Union, enrolled in a randomized...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Jpn J Clin Oncol
Main Authors: Ioka, Tatsuya, Okusaka, Takuji, Ohkawa, Shinichi, Boku, Narikazu, Sawaki, Akira, Fujii, Yosuke, Kamei, Yoichi, Takahashi, Satori, Namazu, Katsushi, Umeyama, Yoshiko, Bycott, Paul, Furuse, Junji
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2015
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4412139/
https://ncbi.nlm.nih.gov/pubmed/25647781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyv011
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados